<?xml version="1.0" encoding="UTF-8"?>
<p>Logistical constraints prevented anti-SARS-CoV-2 antibody characterization of C19-CP prior to transfusion, which likely reflects common current approaches to emergent C19-CP administration. C19-CP from donor 1 likely provided the most significant impact on SARS-CoV-2 eradication given the higher neutralizing titer (
 <xref ref-type="fig" rid="F1">Figure 1C</xref>), which is comparable to US Food and Drug Administration recommendations
 <sup>
  <xref rid="B20" ref-type="bibr">20</xref>
 </sup> and may be sufficient when treating COVID-19 in adults.
 <sup>
  <xref rid="B10" ref-type="bibr">10</xref>
  <xref rid="B11" ref-type="bibr"/>
  <xref rid="B12" ref-type="bibr"/>
  <xref rid="B13" ref-type="bibr"/>
  <xref rid="B14" ref-type="bibr"/>
  <xref rid="B15" ref-type="bibr"/>
  <xref rid="B16" ref-type="bibr"/>
  <xref rid="B17" ref-type="bibr"/>
  <xref rid="B18" ref-type="bibr"/>
  <xref rid="B19" ref-type="bibr"/>
  <xref rid="B20" ref-type="bibr"/>-
  <xref rid="B21" ref-type="bibr">21</xref>
 </sup> This case suggests that such titers may likewise be sufficient in infants. The delay in viral clearance may reflect the time required for C19-CP therapy to effectively eliminate the virus and is consistent with reports in adults with persistent SARS-CoV-2 NAT by NP samples beyond symptom resolution.
 <sup>
  <xref rid="B22" ref-type="bibr">22</xref>,
  <xref rid="B23" ref-type="bibr">23</xref>
 </sup>
</p>
